Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-CRd Before and After Salvage Autologous HCT for Relapsed/Refractory Multiple Myeloma
NCT03556332Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2018
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, carfilzomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2018; status: active, not recruiting.
02
Drugs
daratumumabcarfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03556332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556332.